Selecta Biosciences, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Watertown MA United States (2008)
Status: Acquired by Cartesian Therapeutics (2023)

Organization Overview

First Clinical Trial
2011
NCT01478893
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Selecta Biosciences, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

rapamycin (5 trials)

Drugs in Phase 2 Trials (5)

candida urate oxidase (1 trial)

pegloticase (krystexxa) (1 trial)

pegsiticase (3 trials)

sel-302 (1 trial)

sirolimus (rapamune) (2 trials)

Drugs in Phase 1 Trials (3)

sel-068 (1 trial)

sela-070 (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gout (Phase 3)

Hyperuricemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 9